Biotechnology, Pharmaceuticals, Healthcare/Life Sciences, Regulation/Government Policy, New Products/Services, New Product Approvals, Corporate/Industrial News, Products/Services, Political/General News, Dementia

Biotechnology, Pharmaceuticals

FDA Approval of New Alzheimer’s Drug May Boost Prospects of Other Treatments

The FDA’s reasoning for greenlighting Biogen’s Aduhelm could bode well for other Alzheimer’s drugs targeting the disease in a similar way.

6/9/2021 12:00:00 AM

The Food and Drug Administration’s approval of Biogen's Aduhelm on Monday may have boosted the prospects of other experimental Alzheimer’s disease drugs that target the disease in a similar way

The FDA’s reasoning for greenlighting Biogen’s Aduhelm could bode well for other Alzheimer’s drugs targeting the disease in a similar way.

: The disease can be treated by clearing the buildup of a sticky substance in the brain known as amyloid.Many scientists studying Alzheimer’s aren’t ready to give up on the amyloid hypothesis, but there isn’t a consensus on precisely what role amyloid plays in the disease.

Biographer says Trump is a ‘nefarious performance artist’ COVID-19 live updates: Arkansas sees highest hospitalization increase since start of pandemic Titanic museum iceberg wall collapses, injuring 3 visitors

The FDA on Monday approved Aduhelm, saying the drug reduced amyloid and thereby likely helps Alzheimer’s patients.The decision was cheered by many Alzheimer’s patient groups and doctors, who have lacked good options for treatment. The move was criticized, however, by many researchers who said there wasn’t enough evidence to show the drug worked and at a $56,000 yearly list price, it will be costly.

Read more: The Wall Street Journal »

Progress 77 and Pirs Undocked from Station

The unpiloted Russian Progress 77 cargo spacecraft undocked from the International Space Station while attached to the Pirs docking compartment at 6:55 a.m. EDT.

Who would ever pay privately $56,000 per year, for a clinically ineffective Alzheimer drug? Luxurious care homes in Europe cost much less, and would provide excellent life quality for loved ones. Fahaddurraniii A new breakthrough drug in Alzheimer’s after 2003, but efficacy yet to be established in phase 4 trials. Bhai billion dollars business hai Pharma.

More drugs that showed no functional impact. This will set AD research back years While we try to figure out why proteins misfold in Alzheimers, we're injecting ourselves with synthetic protein inducing transfection agents...sounds just peachy.

Full FDA approval could drive COVID-19 vaccinations, but experts advise against waitingOne-third of unvaccinated U.S. adults say they will only get in line for the COVID-19 jab once it's fully approved, but medical experts say it can also be risky to wait. Why are they so afraid of the covid19 shots And what’s the next excuse after it’s FDA approved? Getting in a car to go somewhere is risky. Going in a plane ✈️ to attend BTC conference is risky Holding US dollars 💵 is risky Life is risky

Explainer: What does FDA approval of Biogen's Alzheimer's drug mean for patients?The U.S. Food and Drug Administration has approved Biogen's aducanumab, the first drug to target an underlying cause of Alzheimer's disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer's drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.

FDA Approves New Drug For Treating Pill DeficienciesWASHINGTON—In what is being considered a major breakthrough for the millions of Americans suffering from a severe lack of capsules and tablets, the FDA announced Friday that it had approved a new drug for treating pill deficiencies. “After months of clinical testing, our studies show that regular usage of this drug provides an immediate boost to the number of caplets in the patient’s body,” said FDA spokesperson Anita Brown-Reed, noting that the fast-acting medication is safe for people of all ages who currently experience symptoms of pill shortage, such as seeing just one or two bottles of medicine in their bathroom cabinet or swallowing capsules twice a week or less. “Certainly those with dangerously low levels of pills may need to take a stronger dosage, possibly three or even four of these 500 mg tablets per day, based on their physician’s recommendation. Overall, however, this treatment appears to provide hope for the countless Americans who are currently living with an entire empty row in their pillbox.” Brown-Reed noted, however, that the new pill may leave patients with an increased risk of co-pays. “this just in, we’re getting reports trustworthy news program, The Onion, is being sued on multiple cases on false information and misinterpretation after a young girl died in Tennessee after her parents followed a guide about pill dosage posted on The Onion‘s twitter account.” I'll take as many pills as they give me as long as I don't have to get vaccinated.

New Alzheimer’s drug is 1st of its kind to be FDA approvedJUST IN: In a major development for patients and the biotechnology industry, the FDA approves the use of a new drug, aducanumab, for treating early Alzheimer’s disease. anacpretto Magic 🍄 treats/cures as well. And it's free Unfortunate it was given a name that’s hard to remember.

In controversial decision, FDA approves first new Alzheimer's disease drug in nearly 20 yearsThe US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment. Have you heard about Longrich financial disbustment? Need access to instant Loan with zero collateral ? Let's chat whatsapp +2348026822351 FDA gives into big business. Joke. Talk about Z*ionist crimes against your fellow journalists .. against paramedics and patients.. against children😭 against innocent people in Palestine 🇵🇸 are u blind?

FDA Approves First New Alzheimer’s Drug in Nearly Two DecadesThe approval of the Biogen drug, which has the molecular name aducanumab and will be sold as Aduhelm, marked a watershed in Alzheimer’s drug research after billions of dollars in investment. but they forgot where they put it